

A REVIEW ON BIOLOGICAL ACTIVITIES OF COUMARIN DERIVATIVES

Sarah A. Hameed^{1*}, Manal Hatem Ahmed², Diyar Adel Lateef³

¹University of Ibn Sina, Baghdad-Iraq.

²College of Pharmacy, Al-Nahrain University, Baghdad, Iraq.

³Al-Nahrain University /College of Medicine / Department of Chemistry and Biochemistry.

Article Received: 13 August 2023 | Article Revised: 06 October 2023 | Article Accepted: 28 November 2023

Corresponding Author: Sarah A. Hameed

University of Ibn Sina, Baghdad-Iraq.

ABSTRACT

Coumarins, which are derived from plants, encompass a wide range of structurally diverse natural substances that exhibit various bioactivities. The aim of this paper is to present an introduction to coumarins and their applications as medicinal agents. Coumarin, a heterocyclic compound formed by the fusion of a benzene ring and a pyrone ring containing oxygen, and its derivatives are widely recognized due to their diverse biological activity and clinical applications. These compounds are highly effective in terms of their inhibitory activity and favorable selectivity ratio. Coumarins are considered a promising category of bioactive heterocyclic compounds that demonstrate a multitude of biological activities, such as antimicrobial, antiviral, antidiabetic, anticancer, antioxidant, antiparasitic, anthelmintic, antiproliferative, anticonvulsant, anti-inflammatory, and antihypertensive activities, among others. The information provided in this manuscript could potentially aid in further research on the development of improved antimicrobial agents with reduced microbial resistance and enhanced antimicrobial profile.

KEYWORDS: Coumarin, Coumarin derivatives, Antimicrobial activity.


INTRODUCTION

Many reports have demonstrated that compounds of coumarin, both natural and synthetic, possess antibacterial action.^[1-14] These compounds, which include Novobiocin and Chlorobiocin, have a coumarin skeleton and have been shown to be effective antibacterial agents. There have also been reports of the diverse activity of a number of additional Coumarin derivatives, such as antiviral, anticoagulant, antioxidant, anti-HIV, anti-allergic, and anti-cancer properties.^[15-17] It has been shown that an increase in biological activity occurs when two heterocyclic systems that are biodynamically coupled together. Drug resistance has grown to be a significant concern in the management of bacterial and fungal-caused infectious illnesses. Resistance to conventional antibiotics has increased due to the increasing rate of bacterial and fungal resistance development.^[20,19,18] As a result, the creation of potent antibacterial and antifungal medications with unique modes of action is desperately needed, and this area of study has taken center stage in programs that study infectious diseases.^[21] A wide variety of biological activities are displayed by coumarins, including


sedative and hypnotic, analgesic, anticoagulant, estrogenic, dermal photosensitizing, antimicrobial, vasodilator, molluscicidal, and hypothermic effects.^[22] Moreover, coumarins' pharmacological characteristics and therapeutic uses depend on the pattern of substitution; more recently, it has been discovered that they exhibit a variety of pharmacological actions, including antibacterial activity. Following up on earlier coumarin research projects.^[23-32] This study offers an in-depth analysis of the most recent coumarin compounds that exhibit antioxidant properties.

Biological Activity

Olayinka O. Ajani et al. reported the synthesis and analysis of the biological activities of many substituted coumarins in their study. The compounds (1, 2, 3, 4) demonstrated significant effectiveness against *Bacillus subtilis*, *Escherichia coli*, and *Staphylococcus aureus*.^[33] Additionally, 4-[(5-mercapto-4-phenyl-4H-1,2,4-triazol-3-yl)-methoxy]-2H-chromen-2-one was produced as a coumarin derivative in a work by Al-Amiery et al. By assessing the inhibition rates of the mycelia of *Aspergillus niger* and *Candida albicans* strains in Potato Dextrose Broth medium (PDB) at concentrations ranging from 10 to 100 µg/ml, they evaluated the antifungal activity of these compounds. It's interesting to note that two compounds (5,6) showed strong antifungal activity that was on par with the common medication fluconazole.^[34]




8-amino-4,7-dihydroxy-chromen-2-one is one of the coumarin derivatives that Behrami and associates synthesized. These compounds' antimicrobial qualities were also assessed.




The effects of standard streptomycin and cefalexine against *Staphylococcus aureus*, *Bacillus subtilis*, and *Escherichia coli* were studied at dosages of 2 mg/ml, 3 mg/ml, and 5 mg/ml. One particular chemical, number seven, showed less action than streptomycin but more activity than cefalexine. Out of all the chemicals that were created, this one also showed the highest level of activity.^[35]

Researchers Vyas et al. synthesized new 3-[(3-(2'-Nitrophenyl))2-propenoyl]-4-hydroxy-6-methyl-2H-chromene-2-ones (8) and evaluated their in vitro antibacterial activity against *Aspergillus niger* and four bacterial strains: *Bacillus*


megaterium, *Proteus vulgaris*, *Escherichia coli*, and *Staphylococcus aureus*. Comparing the extremely active chemical to the mainstream medications ampicillin (16 mm) and amoxicillin (17 mm), the compound demonstrated a zone of inhibition of 25 mm as an antibacterial agent against *Escherichia coli*.



The zone of inhibition for erythromycin was 22 mm, whereas the zone for ciprofloxacin was 26 mm. When ciprofloxacinin was used against *Aspergillus niger*, it showed a 23 mm zone of inhibition as opposed to the 21 mm zone of inhibition of griseofulvin, the conventional medication.^[36] The synthesis of new coumarin derivatives was the focus of this work by Behrami et al. Three bacterial strains were tested for the antibacterial activity of these produced compounds, as well as common medications like cefalexine and streptomycin: *Staphylococcus aureus*, *Escherichia coli*, and *Bacillus cereus*. At two, three, and five milligrams per milliliter, one




compound (9) demonstrated a notable antibacterial effect against all three bacterial strains.^[37]



A novel family of cephalosporins and sulfones containing a coumarin substitution at the 7-position was synthesized by Bonsignore et al. Following synthesis, the compounds were tested using different concentrations of the antibiotic cefotaxime (ranging from 0.125 to 256 µg/ml) against *Staphylococcus aureus* (ATCC 25923), *Escherichia coli* (ATCC 25922), and *Pseudomonas aeruginosa* (ATCC 27853). While the sulfones showed no discernible effect, the


cephalosporins showed potential activity against Gram-positive bacteria. Additionally, a correlation between sulfone and ampicillin was found to inhibit Gram-positive germs, with a minimum inhibitory concentration (MIC) value that was lower than that of ampicillin alone.^[38]

Sahoo and colleagues synthesized new coumarin derivatives and assessed their antibacterial efficacy against *Escherichia coli* and *Staphylococcus aureus*, two types of bacteria that are Gram-positive and Gram-negative, respectively. In the trials, dimethyl sulfoxide (DMSO) was used as a control. Comparing compound 10 to the common medication amoxicillin, compound 10 had the strongest antibacterial activity of all the compounds examined. It is possible that the presence of chlorine on the aromatic ring of the coumarins is responsible for this increased activity. At a concentration level of 0.1 ml, the other chemicals also showed mild to moderate efficacy against both species.^[39]



(10)


A study on the synthesis and biological characteristics of several substituted 3-(4-hydroxybenzoyl)-1H-isochromen-1-one, 2-benzopyran-1H-2-one, 1-H-2-oxo-benzopyran-3-carboxylic acids, and 2-benzofuran-1H-one was presented by Purohit and associates. Purohit et al.^[40] reported that the compounds had noteworthy effectiveness in combating *Staphylococcus aureus* and *Escherichia coli*.



(11)

In a research project, Mohamed and associates created novel 8-ethoxycoumarin compounds. The antibacterial properties of these compounds were further investigated in lab settings. The antimicrobial activities were assessed against four different strains of Gram-positive bacteria: *Bacillus pumilus* (ATCC 14884), *Bacillus subtilis* (ATCC 6633), *Staphylococcus aureus* (ATCC 29737), and *Staphylococcus epidermidis* (ATCC 12228). The two strains of Gram-negative bacteria were *Bor-detella bronchiseptica* (ATCC 4617) and *Escherichia coli* (ATCC 14169). Furthermore, the screening procedure included two different species of fungi: *Saccharomyces cervesia* (ATCC 9080) and *Candida albicans* (ATCC 10231). A specific chemical (12) exhibited a wide range of antibacterial activity against every tested type of bacteria and fungal. Comparing this chemical to ampicillin (25µg/ml) and mycostatin (25µg/ml), better results were obtained. The substitution of a side chain for a hydrogen atom bonded to the coumarin nucleus at position C-3 was identified as the cause of the increased activity. Conversely, the residual compounds that had distinct


side chains had variable levels of moderate to weak antibacterial activity. Sadly, we were unable to paraphrase the input text's final sentence. As a result, nothing changes.^[41]



By adding isoxazoles, pyrimidines, and 1,5-benzothiazole to a parent 4-hydroxycoumarin molecule, Mulwad VV et al. synthesized a variety of heterocycles that improved the biological characteristics of the original molecule. Subsequently, the antibacterial activity of these compounds was evaluated in vitro.^[42]


3-amino-(N-aryl substituted)-6-bromo-2H-1-benzopyran-2-ones and 6-bromo-3-phenoxy substituted were synthesized by Gupta AS et al. 2-H-1-benzopyran-2-ones. After being screened for in-vitro antitubercular efficacy against highly virulent H37Rv strains of mycobacterium tuberculosis, these newly synthesized compounds were compared to streptomycin and INH.^[43,44]

The synthesis of acyl coumarins, 4-hydroxy and 7-hydroxycoumarins, and coumaric amide dimers was carried out by Lin et al. These substances were then tested against strains of *Pseudomonas aeruginosa* (BCRC 11733), *Bacillus subtilis* (BCRC 10029), *Staphylococcus aureus* (BCRC 11863), and *Escherichia coli* (BCRC 11758). Penicillin G potassium salt (CAS 113-98-4, USP grade) was used as a reference medication. Compound 13 showed the highest potency against *Bacillus subtilis* among the investigated compounds, with a minimum inhibitory concentration (MIC) of 8 µg/ml.^[45] in




Novel 1,3-dipolar cycloadducts of 3-azidoacetylcoumarins have been successfully synthesized by Kusanur and colleagues using dimethyl acetylene dicarboxylate (DMAD). These recently created compounds' and their adducts' antibacterial activity were thoroughly assessed, with encouraging results. Al-Haiza and his group also generated and evaluated ⁴⁶ samples of pyridino[3',2'-6,5]-, pyrrolo[3',2'-5,6]-, and [5',4'-6,5]-.Pyrano-4H [3,2-c][1]benzopyran-6-one derivatives for their effectiveness against a range of bacterial strains, including fungi (*Aspergillus niger*, *Penicillium*

italicum, Fusarium oxysporum) and Gram positive bacteria (Staphylococcus aureus, Bacillus subtilis, Bacillus cereus) and Gram negative bacteria (Pseudomonas aurignosa, Echerichia coli, and Enterobacter aerogenes). Amoxicillin and mycostatin, typical medications for bacteria and fungi, respectively, were used at a concentration of 1000 ppm to guarantee reliable comparisons. It is worth noting that compound number fourteen had remarkable antibacterial activity against Enterobacter aerogenes.^[47]




(14)

In a work by Vaso et al., they synthesized numerous novel derivatives at doses of 2 mgml⁻¹, 3 mgml⁻¹, and 5 mgml⁻¹ of 2H-[1]-benzopyran-2-one (coumarin). The antibacterial activity of these substances was subsequently evaluated against three distinct bacterial cultures: Escherichia coli and two Gram positive bacteria, Staphylococcus aureus and Bacillus aureus. The outcomes were contrasted with those of Cephalexine and Streptomycine, two common antibiotics. Compound 15 demonstrated more antibacterial action against Staphylococcus aureus than Cephalexine, but lesser activity against Streptomycine.^[48]




(15)


When Cacic et al. synthesized derivatives of (7-hydroxy-2-oxo-2H-chromen-4-yl)-acetic acid hydrazide (16), they discovered that Staphylococcus pneumoniae was very susceptible to their antibacterial action. In comparison to the normal medication, these compounds exhibited slightly lower levels of activity against Pseudomonas aeruginosa, Bacillus subtilis, Bacillus cereus, and Salmonella panama.^[49]




Schiff's bases, namely 3-(4-(4-(substituted phenyl)prop-1-ene-3-one)phenylimino) methyl)-4-chloro-2H-chromen-2-ones, were synthesized by Kudale et al. The gram positive bacteria *Staphylococcus aureus* (ATCC 9144), *Bacillus subtilis* (ATCC 6633), and *Staphylococcus epidermis* (ATCC 12228) as well as the gram negative bacteria *Escherichia coli* (ATCC 25922), *Salmonella typhi*, and *Pseudomonas aeruginosa* (ATCC 9027) were tested in vitro using these compounds. Moreover, the antifungal activity of these compounds was assessed against two reference medications for antibacterial and antifungal activities, respectively, *Aspergillus niger* (ATCC 10594) and *Clostridium albicans* (ATCC 10231). These standard drugs were amoxicillin and fluconazole. Compound 17 had the highest level of activity among all the investigated compounds, with a minimum inhibitory concentration (MIC) of 20µgml⁻¹.^[50]



Bis[N-(4-oxocoumarinylmethylene)]-1,4-di-amines were synthesized by Hamdi et al. and their antibacterial activity was evaluated against *Staphylococcus aureus* (ATCC 25923) at a concentration of 106CFCml⁻¹ on a Mueller-Hinton agar plate. The chemical with the most potent antibacterial activity was one.⁵¹ Mashelkar et al. synthesized new 4-substituted coumarins and tested them against *Salmonella typhi* and Gram positive and negative *Staphylococcus aureus* in vitro. The typical medications were trimethoprim and ampicillin. Significant antibacterial activity was demonstrated by two compounds (18a-18b) against *Staphylococcus aureus* and *Salmonella typhi* at doses ranging from 10 to 200µgml⁻¹.⁵² Dekic and colleagues produced and assessed 4-arylamino-3-nitrocoumarins.




Salmonella enterica (ATCC 13076), *Klebsiella pneumoniae* (ATCC 10031), *Aspergillus niger* (ATCC 16404), and yeast *Candida albicans* (ATCC 10231). Among the compounds in the series, compound 19 demonstrated the highest anticandidal activity. The reference medications were nystatine and tetracycline.^[53]




(19)

A number of novel carboxylate ligands generated from coumarin, together with their silver(I) complexes, were synthesized and described by Creaven et al. Following that, these substances were tested for their antifungal and in-vitro antibacterial activities against a variety of Gram positive and Gram negative bacteria. A number of the Ag(I) complexes exhibited strong antibacterial activity, although the ligands themselves showed no such activity. Ag(I) complexes of hydroxy-substituted coumarin carboxylates in particular showed strong activity.^[54]




(20)

Researchers produced 4-Heteroaryl-coumarin-3-carbaldehydes and examined their antibacterial activities against a range of bacteria, including *Pseudomonas aeruginosa*, *Hafnia alvei*, *Escherichia coli*, and *Enterobacter cloacae*, in the study done by Govori et al. Using the Agar disc diffusion technique, the inhibition zone surrounding the agar discs that were soaked in N,N-DMF solution of the compounds at doses of 1, 3, and 5 mg/ml was evaluated. One particular chemical (21) was found to have stronger antibacterial efficacy against *Staphylococcus aureus*, *Escherichia coli*, and *Enterobacter cloaco*, but not against *Hafnia alvei* or *Pseudomonas aeruginosa*.^[55]




(21)


Mulwad VV et al. produced 4-[1-(2H-[1]-4-hydroxy-2-oxo-benzopyran-3-yl)methylidene] in a different investigation.[1,2,4]triazine-6-one and its derivatives, as well as -2-phenyl-4H-oxazol-5-ones. After screening all of the synthesized compounds for antibacterial activity, it was discovered that they all showed a considerable amount of activity against the tested microorganisms.^[56] Furthermore, a unique series of 5H,7H-N-(coumarin-6-yl) was synthesized by Choudhari et al. The antibacterial and antifungal activity of -2,8-diphenyl-5,7-dioxo-6-(7-methoxy-4-methyl coumarin-6-yl)-4,5,6,7-tetrahydrobenzimidazo[5,6-c]pyrrole derivatives (22) was assessed against *Salmonella typhi*, *Clostridium albicans*, *Aspergillus niger*, and *Staphylococcus aureus*. The substances exhibited antibacterial properties, with minimum inhibitory concentrations (MIC) varying between 50µg and 200µg per milliliter.^[57]



In order to evaluate the microbiological activity of their newly produced 3-cynamoyl-4-hydroxycoumarins (23) against a range of bacteria, including *Pseudomonas aeruginosa*, *Echerichia coli*, *Salmonella typhimurium*, *Bordatella bronchiseptica*, *Bacillus subtilis*, and *Staphylococcus aureus*, Završnik D et al. The compounds containing halogens had the highest levels of microbiological activity; particularly efficient against *Bacillus subtilis* were those containing 4-Br and 4-Cl, while the most effective molecule against *Staphylococcus aureus* was one containing 4-Cl.^[58]




Similarly, N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides, also known as coumarin-3-carboxamides, were synthesized and tested by Chimenti F et al. as anti-*Helicobacter pylori* drugs. The compounds with a 4-acyl phenyl group demonstrated the best activity against *Helicobacter pylori* metronidazole resistant strains, despite the synthesized compounds having little to no activity against different species of Gram positive and Gram negative bacteria and strains of pathogenic fungi.^[59]




(24)

4-aryl-2,6-di(coumarin-3-yl)pyridines (25) were synthesized by Patel AK et al. and their antibacterial activity was evaluated. Against *Aspergillus niger*, none of the compounds exhibited antifungal activity. The findings showed that all of the compounds had comparable antibacterial activity and that the presence of substituents such -CH₃ or -OCH₃ in either the coumarin nucleus or a phenyl ring did not significantly impact the activity. Moreover, the antibacterial activity against *Escherichia coli* was decreased by the insertion of an additional fused benzene ring between the C-5' and C-6' sites.^[60]



(25)


Last but not least, Rama Ganesh et al. created coumarin derivatives with thiazolidin-4-one rings and assessed their antibacterial efficacy against both Gram negative and Gram positive bacteria, such as *Escherichia coli* and *Klebsiella pneumoniae*. It was discovered that the most active chemical (26) had a 20 mm zone of inhibition against *Bacillus subtilis* and *Staphylococcus aureus*.^[61]




(26)

4-methyl-3-phenyl-6-[4-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-6-aryl-pyridin-2-yl]coumarin derivatives (27) were synthesized by Brahm Bhatt et al. and screened using the agar cup diffusion method for antibacterial activity against *Escherichia coli* and antifungal activity against *Candida albicans*. DMF was utilized as a blank, 1000 µg/ml–1 concentrations of streptomycin and clotrimazole were used as anti-bacterial and anti-fungal standard drugs,


respectively. When compared to a normal medication, the synthetic compounds exhibited lower levels of activity against both gram positive and gram negative microorganisms.^[62]



A series of 2-(substitutedphenyl)-3-[3-(2-oxo-2H-coumarin-3-yl)] was synthesized by Bhatt et al. The compound 5-thioxo-1,5-dihydro-4H-1,2,4-triazol-4-yl-1,3-thiazolidin-4-ones and evaluated their antifungal and antibacterial efficaciousness against *Clostridium albicans* and Gram-positive and Gram-negative strains of *Escherichia coli*. For comparison, the common antibacterial medication ciprofloxacin and the antifungal medication ketoconazole were used. A concentration of 100µg/mL was used to evaluate the test substances and reference medications. DMF, or N,N-dimethylformamide, served as both the solvent and the control. In comparison to *Staphylococcus aureus*, *Escherichia coli*, and *Clostridium albicans*, compound 28 demonstrated growth suppression of 92%, 80%, and 90%, respectively.^[63]




Cu(II) complexes and a sequence of Schiff bases were synthesized by Creaven et al. (29a-29b). All of the free ligands and their metal complexes were compared to amphotericin B and ketoconazole for their antifungal activity. When compared to their respective reference medications, several of the metal complexes exhibited strong antibacterial activity, but the ligands themselves showed little antimicrobial action.^[64]




In vitro tests were conducted by Bairagi et al. to evaluate the antimicrobial activity of 4-chloro-3-((substituted phenylimino)methyl)-2H-chromen-2-ones against Gram positive bacteria, *Bacillus subtilis* (ATCC 2063), and Gram negative bacteria, *Escherichia coli* (ATCC 20931), as well as fungi, *Aspergillus niger* (ATCC 16404) and *Candida*

albicans (ATCC 10231). Compound 30 showed the maximum activity, with a minimum inhibitory concentration of 15 µg/ml, against all tested species. The conventional medications for their antibacterial and antifungal properties were amoxicillin and fluconazole, respectively.^[65]




(30)

The Agar disc diffusion technique was utilized to measure the diameters of the inhibition zone surrounding discs that had been previously wetted with N,N-DMF solution of compounds at concentrations of 1, 3, and 5 mg/ml. This allowed for an evaluation of the compounds' activity against *Hafnia alvei*, *Pseudomonas aeruginosa*, *Enterobacter cloacae*, *Staphylococcus aureus*, and *Escherichia coli*. Compound 31 shown greater antibacterial efficacy against *Enterobacter cloacae*, *Escherichia coli*, and *Staphylococcus aureus*, but not against *Hafnia alvei* or *Pseudomonas aeruginosa*.^[66]




(31)


The authors, Mladenovic et al., synthesized novel derivatives of 4-hydroxy-chromene-2-one and screened them for antibacterial activity against *Escherichia coli*, *Bacillus subtilis*, and Gram positive and negative bacteria, *Staphylococcus aureus*, as well as for antifungal activity against *M. mucedo* and *Candida albicans*. For comparison, the antifungal medicine ketoconazole and the common antibacterial antibiotic streptomycin were utilized. Compound 32 demonstrated efficacy against *M. mucedo* equivalent to that of the reference medication ketoconazole (31.25 µg/ml).^[67]




(32)




Basanagouda and colleagues (36) produced 4-aryloxymethylcoumarins and used the disc diffusion method to screen for antibacterial and antifungal activity at various doses (500, 250, 100, and 50 $\mu\text{g/ml}$). The antibacterial activity was evaluated against three Gram-negative bacteria (*Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Escherichia coli*) and two Gram-positive bacteria (*Streptococcus faecalis* and *Staphylococcus aureus*). Conversely, five fungi—*Aspergillus flavus*, *Aspergillus fumigatus*, *Candida albicans*, *Penicillium notatum*, and *Rhizopus*—were used to assess the antifungal activity. The standard antibacterial and antifungal medications used were ciprofloxacin and fluconazole, respectively. It was discovered that compounds with methoxy, chloro, or bromo substituents at the coumarin's C-6 position had antibacterial and antifungal properties.^[71]




Kumbar and colleagues synthesized new coumarin Schiff bases and then tested them for biological activity. Every chemical showed a significant amount of action. Compound 37 had significant anti-tubercular efficacy against *M. tuberculosis* (H37Rv), outperforming the conventional medication isoniazid, which has a MIC value of 0.02 $\mu\text{g/ml}$. Compound 37's MIC value was less than 2 $\mu\text{g/ml}$. The presence of a chloro group at the para and meta locations of the phenyl ring is responsible for this increased activity (Kumbar et al.,).^[72]




Recently, Bhagat et al. created new derivatives of indolinedione-coumarin and tested them against a range of bacterial and fungal strains to determine their antibacterial capabilities. Compounds 4 and 5 had the most antibacterial activity of all the compounds, with MIC values of 30 and 312 $\mu\text{g/mL}$, respectively. According to research on structure-activity connections, the length of the carbon chain and the electronic environment have an impact on antibacterial activity (Bhagat et al.).^[73]




Compound 1's increased antibacterial activity can be explained by the combination of a fluorine group and a pyrimidine ring. Compounds 2 and 3 have antibacterial action in part due to the existence of a heterocyclic ring carrying nitrogen and a chloro substituent.^[74]



Phutdhawong and colleagues synthesized new coumarin-3-carboxamides and assessed their potential anti-tumor effects. Compound 10 showed the greatest activity of all the compounds against the HepG2 and HeLa cancer cell lines, with IC₅₀ values ranging from 2.62 to 4.85 μM and 0.39 to 0.75 μM , each. The existence of a fluorobezamide moiety is responsible for this increased potential (Phutdhawong et al.).^[75]



Novel coumarin compounds were synthesized by Mohamed S. El-Attar et al., who then screened them for antibacterial properties. Additionally, complexes containing these substances were created with three strains of bacteria that are Gram-positive (*Bacillus subtilis*, *Brevibacterium otitidis*, and *B. cereus*) and three strains that are Gram-negative (*Escherichia coli*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*). DMSO-d₆ was used to create the testing solutions (El-Attar et al.).^[76]



CONCLUSION

The remarkable biological traits of coumarins have attracted a great deal of study. Due to their physiological, bacteriostatic, and anti-tumor qualities, these compounds are attractive candidates for more research into backbone derivatization and screening as possible therapeutic agents. The anticancer efficacy of coumarin and its metabolite 7-hydroxycoumarin against a variety of human tumor cell lines has been demonstrated by researchers Weber et al. Furthermore, coumarin and its derivatives have shown encouraging promise in several cancer cell lines as inhibitors of cellular proliferation. There is a great deal of interest in creating new antimicrobial compounds since the compounds have a variety of biological actions and their structures allow for different substitutions.

REFERENCES:

1. Zalfiqar A, Nasim H. *Indian J Chem*, 2007; 46B: 1322.
2. Bernadette S, Denis A, Kevin K. *Inorg Chim Acta*, 2006; 359: 3976.
3. Balaji PN, Sai Sree vani. *J Chem Pharm Res*, 2010; 2(4): 754-8.
4. Gurubasavaraja SPM and Agasimundin YS. *Acta Pharmaceutica Sci*, 50: 197-202.
5. Hwang YH, Cho WK, Jang D, Ha JH, Ma JY. High-performance liquid chromatography determination and pharmacokinetics of coumarin compounds after oral administration of Samul-Tang to rats. *Pharmacogn Mag*, 2014; 10(37): 34-9. doi:10.4103/0973-1296.126656. <https://doi.org/10.4103/0973-1296.126656>.
6. Amarnath A1, Lenin V, Archunan G. Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome. *Pharmacogn Mag*, 2013; 9(35): 264-70. doi:10.4103/0973-1296.113287 <https://doi.org/10.4103/0973-1296.113287>.
7. Sur TK, Hazra AK, Bhattacharyya D, Hazra A. Antiradical and antidiabetic properties of standardized extract of Sunderban mangrove *Rhizophora mucronata*. *Pharmacogn Mag*, 2015; 11(42): 389-94. doi: 10.4103/0973-1296.153094. <https://doi.org/10.4103/0973-1296.153094>.
8. Wangboonskul J, Tunsirikongkon A, Sasithornwetchakun W. Simultaneous determination of nine analytes in *Clausena harmandiana* Pierre. by new developed high-performance liquid chromatography method and the

- influence of locations in Thailand on level of nordentatin and dentatin. *Pharmacogn Mag*, 2015; 11(41): 1-7. doi: 10.4103/0973-1296.149666. <https://doi.org/10.4103/0973-1296.149666>.
9. Latifa A, Mohamed K, Geffroy-Rodier C, Jérôme G, Sami Z. Phytochemical Investigation, Isolation and Characterization of Coumarins from Aerial Parts and Roots of Tunisian *Pituranthos chloranthus* (Apiaceae). *Pharmacognosy Communications*, 2015; 5(4): 237-43. <https://doi.org/10.5530/pc.2015.4.4>.
 10. Ranasinghe P, Perera S, Gunatilake M, Abeywardene E, Gunapala N, Premakumara S, et al. Effects of *Cinnamomum zeylanicum* (Ceylon cinnamon) on blood glucose and lipids in a diabetic and healthy rat model. *Phcog Res.*, 2012; 4(2): 73-9 <https://doi.org/10.4103/0974-8490.94719> PMID: 22518078 PMCID: PMC3326760.
 11. Golfakhrabadi F, Yousefbeyk F, Mirnezami T, Laghaei P, Hajimahmoodi M, Khanavi M. Antioxidant and Antiacetylcholinesterase Activity of *Teucrium hyrcanicum*. *Phcog Res.*, 2015; 7(Suppl S1): 15-9. <https://doi.org/10.4103/0974-8490.157993> PMID: 26109782 PMCID: PMC4466763.
 12. Mahendra P, Bisht S. *Ferula asafoetida*: Traditional uses and pharmacological activity. *Phcog Rev [serial online]* 2012 [cited 2016 Oct 18]; 6: 141-6.
 13. Patel PB, Patel TK, Baxi SN, Acharya HR, Tripathi C. Antitubercular effect of 8-[(4-Chloro phenyl) sulfonyl]-7-Hydroxy-4-Methyl-2H-chromen-2-One in guinea pigs. *J Pharmacol Pharmacother [serial online]* 2011 [cited 2016 Oct 18]; 2: 253-60.
 14. Kokanova-Nedialkova Z, Nedialkov PT, Nikolov SD. The genus *Chenopodium*: Phytochemistry, ethnopharmacology and pharmacology. *Phcog Rev [serial online]* 2009 [cited 2016 Oct 18]; 3: 280-306.
 15. Balaji PN, Indrani PM. *Pelagia Research Library. Der Pharmacia Sinica*, 2010; 3(6): 685-9.
 16. Gummudavelly S, Ranganath Y. *Asian J Research Chem*, 2009; 2(1).
 17. B Ramesh, Sumana T. *E-Journal of Chemistry*, 2010; 7(2): 514-516. <https://doi.org/10.1155/2010/731675>.
 18. Raman N, Sakthivel A, Rajasekaran K. Synthesis and spectral characterization of antifungal sensitive Schiff base transition metal complexes. *Mycobiology*, 2007; 35(3): 150-3. <https://doi.org/10.4489/MYCO.2007.35.3.150> PMID: 24015086 PMCID: PMC3763143.
 19. Rice SA, Givskov M, Steinberg P, Kjelleberg S. Bacterial signals and antagonists: The interaction between bacteria and higher organisms. *J Mol Microbiol Biotechnol*, 1999; 1(1): 23-31. PMID: 10941781.
 20. Kadhim, A. S., & Al-Karawi, A. S., Insights into the Pathogenesis, Virulence Factors, and Diagnosis of *Helicobacter pylori*: A Comprehensive Review. *American Journal of Bioscience and Bioinformatics*, 2023; 2(1): 31-37.
 21. Kumar G; Kumar D, Devi S, Verma R, Johari R. Synthesis, spectral characterization of biologically active compounds derived from oxalyldihydrazide and 5-tertbutyl-2-hydroxy-3-(3- phenylpent-3-yl)benzaldehyde and their Cu(II), Ni(II) and Co(II) Complexes. *Int J Eng Sci Technol*, 2011; 1(3): 1630-54.
 22. Parmer S, Kumar R. Substituted quinazolone hydrazides as possible antituberculous agents. *J Med Chem*, 1968; 11: 635-6. <https://doi.org/10.1021/jm00309a064>.
 23. Al-Amiery A, Al-Majedy Y, Kadhum A. Hydrogen Peroxide Scavenging Activity of Novel Coumarins Synthesized Using Different Approaches. *PLoS ONE*, 2015; 10(7): e0132175.
 24. Al-Amiery AA, Al-Bayati R, Saour K, Radi M. Cytotoxicity, Antioxidant and Antimicrobial activities of novel 2-quinolone derivatives derived from coumarins. *Research on Chemical Intermediates*, 2012; 38(2): 559-69. <https://doi.org/10.1007/s11164-011-0371-2>.

25. Al-Amiery AA, Al-Majedy Kadhun AAH, Mohamad A. Novel macromolecules derived from coumarin: synthesis and antioxidant activity. *Sci Rep*, 2015; 5: 11825. <https://doi.org/10.1038/srep11825> PMID:26134661 PMCID:PMC4488837.
26. Al-Amiery AA, Al-Majedy YK, Al-Duhaidahawi D, Kadhun AAH, Mohamad AB. Green Antioxidants: Synthesis and Scavenging Activity of Coumarin-Thiadiazoles as Potential Antioxidants Complemented by Molecular Modeling Studies. *Free Radicals and Antioxidants*, 2016; 6(2): 173-7. <https://doi.org/10.5530/fra.2016.2.7>.
27. Al-Amiery AA, Al-Majedy YK, Kadhun AA, Mohamad AB. New coumarin derivative as an eco-friendly inhibitor of corrosion of mild steel in acid medium. *Molecules*, 2014; 20(1): 366-83.
28. Al-Amiery AA, Al-Majedy YK, Kadhun AAH, Mohamad AB. Synthesis of new coumarins complemented by quantum chemical studies. *Research on Chemical Intermediates*, 2016; 42(4): 3905-18. <https://doi.org/10.1007/s11164-015-2252-6>.
29. Al-Amiery AA, Kadhun AAH, Mohamad AA. Antifungal Activities of New Coumarins. *Molecules*, 2012; 17(5): 5713-23. <https://doi.org/10.3390/mole> Al-Amiery *et al.*: Coumarins, Based Antimicrobials Systematic Reviews in Pharmacy, Jan-Dec, 2017; 8(1): 69 cules 17055713 PMID:22628043.
30. Al-Amiery AA, Kadhun AAH, Mohamad AB, Musa AY, Li CJ. Electrochemical study on newly synthesized chlorocurcumin as an inhibitor for mild steel corrosion in hydrochloric acid. *Materials*, 2013; 6(12): 5466-77. <https://doi.org/10.3390/ma6125466>.
31. (a). Al-Amiery AA, Musa AY, Kadhun A, Mohamad A. The use of umbelliferone in the synthesis of new heterocyclic compounds. *Molecules*, 2011; 16(8): 6833-43. (b). Al-Azawi F, Al-Baghdadi S, Mohamed A, Al-Amiery A, Abed T, Mohammed S, Kadhun AAH, Mohamad AB. Synthesis, inhibition effects and quantum chemical studies of a novel coumarin derivative on the corrosion of mild steel in. *Chemistry Central Journal*, 2016; 10(1): 1-9. (c). Al-Majedy Y, Al-AmieryA, Kadhun A. Efficient catalyst one-pot synthesis of 3 7-(aryl)-10,10-dimethyl-10,11-dihydrochromeno[4,3-b] 4 chromene-6,8(7H,9H)dione derivatives complemented by antibacterial activity. *Bio Med Research International*, 2016; 2016: 1-7. (d). Al-Majedy Y, Kadhun K, Al-Amiery AAH. A synthesis and characterization of some new 4-Hydroxy-coumarin derivatives. *Molecules*, 2014; 19(8): 11791-9. (e). Al-Majedy YK, Al-Amiery AA, Kadhun AAH, Mohamad AB. Antioxidant Activities of 4-Methylumbelliferone Derivatives. *PLoS ONE*, 2016; 11(5): 1-13. (f). Al-Majedy YK, Al-Duhaidahawi D, Al-Azawi K, Al-Amiery AA, Kadhun AAH, Mohamad AB. Coumarins as Potential Antioxidant Agents Complemented with Suggested Mechanisms and Approved by Molecular Modeling Studies. *Molecules*, 2016; 21: 135-45. <https://doi.org/10.3390/molecules21020135>.
32. Al-Ayed AS. Synthesis, Spectroscopy and Electrochemistry of New 3-(5-Aryl-4,5-Dihydro-1H-Pyrazol-3-yl)-4-Hydroxy-2H- Chromene-2-One 4, 5 as a Novel Class of Potential Anti- bacterial and Antioxidant Derivatives *International Journal of Organic Chemistry*, 2011; 1(03): 87-96.
33. Ajani OO, Nwinyi OC. *Journal of Heterocyclic Chemistry*, 2011; 47: 179-87.
34. Al-AmieryAA, Kadhun AAH, Mohamad AB, Antifungal activities of new coumarins, *Molecules*, 2012; 17: 5713-23. <https://doi.org/10.3390/molecules17055713> PMID:22628043.
35. Behrami A, Krasniqi I. Antibacterial activity of coumarine derivatives synthesized from 8- amino-4,7-dihydroxy-chromen-2-one and comparison with standard drug. *Jrnl of Chemical and Pharm Res*, 2012; 4(5): 2495-500.

36. Vyas KB, Nimavat KS, Joshi KM, Jani GR. Synthesis of 3-[(3-(2'-nitrophenyl))-prop-2-enoyl]-4-hydroxy-6-methyl-2H-chromene-2-one and its metal complexes as antimicrobial agent. *Jrnl of Chemical and Pharm Res*, 2012; 4(5): 2720-3.
37. Behrami A, Krasniqi I, Demaku S. Antibacterial activity of coumarine derivatives synthesized from 4,7-dihydroxy-2-oxo-2H-chromene-3-carbaldehyde and comparison with standard drug, *Int Jrnl of Res in Pharm and Biomed Sci*, 2012; 3(3): 1306-11.
38. Bonsignore L, Cottiglia F, Elkhaili H, Jehl F, Lavagna SM, Loy G, Fedele MB, Monteil H, Pompei D, Secci D. Synthesis and antimicrobial activity of coumarin 7-substituted cephalosporins and sulfones, *Farmaco*, 1998; 53(6): 425-30. [https://doi.org/10.1016/S0014-827X\(98\)00047-0](https://doi.org/10.1016/S0014-827X(98)00047-0).
39. Sahoo SS, Shukla S, Nandy S, Sahoo HB. Synthesis of novel coumarin derivatives and its biological evaluations. *Eur Journal of Experimental Bio*, 2012; 2(4): 899-908.
40. Purohit NV. Synthesis and studies on biological activities of some substituted 2-benzopyran-1H-one, 1H-2-oxo-benzopyran-3-carboxylic acids and 2-benzofuran-1H-one. *Ind J Chem*, 2001; 40B: 222-7.
41. Mohamed HM, El-Wahab A, Ahmed KA, El-Agrody AM, Bedair AH, Eid FA, et al. Synthesis, reactions and antimicrobial activities of 8-ethoxycoumarinderivatives, *Molecules*, 2012; 17: 971-88. <https://doi.org/10.3390/molecules17010971> PMID:22258342.
42. Mulwad VV, Pawar RB. Synthesis of some antibacterial compounds from 4-hydroxycoumarin. *Indian J Chem Section B.*, 2003; 42: 2091-6. <https://doi.org/10.1002/chin.200352140>.
43. Gupta AS, Phull MS. A convenient one-pot synthesis and antitubercular activity of coumarin derivative containing sulphanimide group: Part II. *Indian J Chem Section B.*, 1996; 35(3): 276-7.
44. Gupta AS, Prabhu BS. Synthesis of 3-amino-(N-aryl substituted)-6-bromo-2H-1-benzopyran-2-ones and 6-bromo-3-phenoxy substituted-2H-1-benzopyran-2-ones as potential antitubercular agents: Part I. *Indian J Chem Section B.*, 1996; 35(2): 170-1.
45. Lin PY, Yeh KS, Su CL, Sheu SY, Chen T, Ou KL, et al. Synthesis and Antibacterial Activities of Novel 4-Hydroxy-7-hydroxy-and 3-Carboxycoumarin Derivatives. *Molecules*, 2012; 17(9): 10846-63. <https://doi.org/10.3390/molecules170910846> PMID: 22964501.
46. Kusanur RA, Kulkarni MV. New 1,3-dipolar cycloadducts of 3-azidoacetylcoumarins with DMAD and their antimicrobial activity. *Indian J Chem Section B.*, 2005; 44: 591-4. <https://doi.org/10.1002/chin.200528145>.
47. Al-Haiza MA, Mostafa MS, El-Kady MY. Synthesis and biological evaluation of some new coumarin derivatives. *Molecules*, 2003; 8: 275-86. <https://doi.org/10.3390/80200275>.
48. Vaso K, Behrami A, Govori S. Synthesis and antibacterial activity of 4-(4-hydroxyphenylamine)-3-[1-(phenylhydrazine)]-2H-[1]-benzopyran-2-one. The comparison of the antibacterial activity with standard drugs. *Natura Montenegrina*, 2012; 11(1): 93-103.
49. Cacic M, Trkovnik M, Cacic F, Has-Schon E. Synthesis and antimicrobial activity of some derivatives of (7-hydroxy-2-oxo-2H-chromen-4-yl)-acetic acid hydrazide. *Molecules*, 2006; 11(2): 134-47. <https://doi.org/10.3390/11010134> PMID: 17962784.
50. Kudale SD, Deodhar MN. Synthesis and evaluation of some coumarin containing potential antimicrobial agents. *E-Journal of Chemistry*, 2012; 9(4): 2493-500. <https://doi.org/10.1155/2012/953564>.
51. Hamdi N, Lidrissi C, Saoud M, Nieves AR, Zarrouk H. Synthesis of some new biologically active coumarin derivatives. *Chem of Heterocyclic Compounds*, 2006; 42(3): 320-5. <https://doi.org/10.1007/s10593-006-0088-0>.

52. Mashelkar UC, Audi AA. Synthesis of some novel 4-substituted coumarins having potential biological activity (Part III). *Ind Jnl of Chem* 45B, 2006; 1463-1469.
53. Dekic V, Radulovic N, Vukićević R, Dekic B, Stojanovic-Radic Z, Palic R. Influence of the aryl substituent identity in 4-arylamino-3-nitrocoumarins on their antimicrobial activity. *African Jnl of Pharmacy and Pharmacology*, 2011; 5(3): 371-5. <https://doi.org/10.5897/AJPP10.408>.
54. Creaven BS, Egan DA, Kavanagh K, McCann M, Noble A, Thati B, et al. Synthesis, characterization and antimicrobial activity of a series of substituted coumarin-3-carboxylato silver(I) complexes. *Inorganica Chimica Acta*, 2006; 359: 3976-84. <https://doi.org/10.1016/j.ica.2006.04.006>.
55. Govori S, Spahiu S, Kalaj V, Leci O, Haziri A, Ibrahim H. Antimicrobial properties of newly synthesized derivatives of coumarine. *Am J of Biochem and Biotech*, 2010; 6(4): 275-8. <https://doi.org/10.3844/ajbbsp.2010.275.278>.
56. Mulwad VV, Satwe DS. Synthesis of biologically active 4-[1-(2H-[1]-4-hydroxy-2-oxo-benzopyran-3-yl)methylidene]-2-phenyl-4H-oxazol-5-ones and [1,2,4] triazine-6-one and its derivatives. *Indian J Chem Section B.*, 2006; 45: 1210-5. <https://doi.org/10.1002/chin.200638127>.
57. Choudhari BP, Mulwad VV. Synthesis and antimicrobial screening of 5H,7H-N-(coumarin-6-yl)-2,8-diphenyl-5,7-dioxo-4,5,6,7-tetrahydrobenzimidazo[5,6-c]-furan and 5H,7H-N-(coumarin-6-yl)-2,8-diphenyl-5,7-dioxo-6-(7-methoxy-4-methylcoumarin-6-yl)-4,5,6,7-tetrahydrobenzimidazo[5,6-c]pyrrole. *Ind J of Chem* 45B, 2006; 314-7. <https://doi.org/10.1002/chin.200619120>.
58. Završnik D, Halilović SS, Softić D. Synthesis, structure and antibacterial activity of 3-substituted derivatives of 4-hydroxycoumarin. *Periodicum Biologorum*, 2011; 113(1): 93-7.
59. Chimenti F, Bizzarri B, Bolasco A, Secci D, Chimenti P, Carradori S. Synthesis and in vitro selective anti-*Helicobacter pylori* activity of N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides. *Eur J Med Chem*, 2006; 41: 208-12. <https://doi.org/10.1016/j.ejmech.2005.11.001> PMID:16377035.
60. Patel AK, Patel NH, Patel MA, Brahmabhatt DI. Synthesis, characterization and antimicrobial activity of some 4-aryl-2,6-di(coumarin-3-yl)pyridines. *ARKIVOC*. 2010, xi, 28-38.
61. Rama Ganesh CK, Yadav DB, Venkatesh KB. Synthesis and biological evaluation of some innovative coumarin derivatives containing thiazolidin-4-one ring. *Ind Jnl of Chem* 49B, 2010; 1151-4.
62. Brahmabhatt DI, Kaneria AR, Patel AK, Patel NH. Synthesis and antimicrobial screening of some 3-[4-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-6-aryl-pyridin-2-yl] and 4-methyl-3-phenyl-6-[4-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-6-aryl-pyridin-2-yl]coumarins. *Ind Jnl of Chem* 49B, 2010; 971-7. <https://doi.org/10.1002/chin.201047141>.
63. Bhat MA, Siddiqui N, Khan SA, Mohamed MI. Synthesis of triazolothiazolidi Al-Amiery *et al.*: Coumarins, Based Antimicrobials 70 Systematic Reviews in Pharmacy, Vol 8, Issue 1, Jan-Dec, 2017 none derivatives of coumarin with antimicrobial activity. *Acta Poloniae Pharmaceutica Drug Res*, 2009; 66(6): 625-32.
64. Creaven BS, Devereux M, Karcz D, Kellett A, McCann M, Noble A, Walsh M. Copper(II) complexes of coumarin-derived Schiff bases and their anti-*Candida* activity. *J of Inorg Biochem*, 2009; 103(9): 1196-203. <https://doi.org/10.1016/j.jinorgbio.2009.05.017> PMID:19631386.
65. Bairagi S, Bhosale A, Deodhar MN. Design, synthesis and evaluation of schiff's bases of 4-chloro-3-coumarin aldehyde as antimicrobial agents. *E-Journal of Chemistry*, 2009; 6(3): 759-62. <https://doi.org/10.1155/2009/874389>.

66. Govori S, Spahiu S, Kalaj V, Leci O, Haziri A, Ibrahim H. Antimicrobial properties of newly synthesized derivatives of coumarine. *Am J of Biochem and Biotech*, 2010; 6(4): 275-8. <https://doi.org/10.3844/ajbbbsp.2010.275.278>.
67. M ladenovic M , Vukovic N, Sukdolak S, Solujic S. Design of novel 4-hydroxychromene-2- one derivatives as antimicrobial agents. *Molecules*, 2010; 15: 4294-308. <https://doi.org/10.3390/molecules15064294> PMID:20657442.
68. Singh I, Kaur H, Kumar S, Kumar A, Lata S, Kumar A. Synthesis of new coumarin derivatives as antibacterial agents. *Int Jrnl of Chem Tech Res.*, 2010; 2(3): 1745-52.
69. Porwal B, Jayashree BS, Attimarad M. Synthesis of some new 3- coumarinoylpyridinium and quinolinium bromides for their antimicrobial activity. *Jrnl Basic Clin Pharm*, 2009; 1(1): 29-32. PMID:25206250.
70. Sandeep G, Ranganath YS, Bhasker S, Rajkumar N. Synthesis and biological screening of some novel coumarin derivatives. *Asian J Res Chem*, 2009; 2(1): 46-8.
71. Basanagouda M, Kulkarni MV, Sharma D, Gupta VK, Pranasha, Sandhyarani P, et al. Synthesis of some new 4- aryloxymethylcoumarins and examination of their antibacterial and antifungal activities. *J Chem Sci*, 2009; 121(4): 485-95. <https://doi.org/10.1007/s12039-009-0058-z>.
72. S.S. Kumbar, *et al.* Functionalization of 3-chloroformylcoumarin to coumarin Schiff bases using reusable catalyst: an approach to molecular docking and biological studies, *R. Soc. open sci.*, 5(2018): Article 172416, 10.1098/rsos.172416.
73. K. Bhagat, *et al.* Design, synthesis, antimicrobial evaluation, and molecular modeling studies of novel indolinedione–coumarin molecular hybrids *ACS Omega*, 2019; 4: 8720-8730, 10.1021/acsomega.8b02481.
74. M. Nibin Joy, *et al.* Synthesis of coumarins coupled with benzamides as potent antimicrobial agents *Pharm. Chem. J.*, 2020; 54: 604-621, 10.1007/s11094-020-02245-4.
75. W. Phutdhawong, *et al.* Synthesis and biological activity evaluation of coumarin-3- carboxamide derivatives *Molecules*, 2021; 26: p. 1653, 10.3390/molecules2606165.
76. Mohamed S. El-Attar et al. Spectroscopic Analyses and Antimicrobial Activity of Novel Ciprofloxacin and 7-Hydroxy-4-methylcoumarin, the Plant-Based Natural Benzopyrone Derivative. *J. Mol. Sci.*, 2022; 23(14): 8019; <https://doi.org/10.3390/ijms23148019>.